SGLT2 Inhibitor

Any inhibitor of the sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. By binding to and blocking SGLT2, these… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE Insulin adjustments to maintain glycemic control in individuals with type 1 diabetes often lead to wide glucose… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years. Consequently, the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AIM This Phase IIb, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability and… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to… (More)
  • table 1
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting sodium-glucose cotransporter-2 (SGLT2). It was… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE The inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach… (More)
Is this relevant?